Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of icotinib in combination
with whole brain radiotherapy for NSCLC patients with brain metastases. The primary endpoint
is objective response rate of intracranial lesions.